A141080 Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
LigaChem Biosciences Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩74,800.00 |
52 Week High | ₩84,000.00 |
52 Week Low | ₩31,200.00 |
Beta | 0.98 |
11 Month Change | 17.43% |
3 Month Change | 14.90% |
1 Year Change | 107.20% |
33 Year Change | 19.68% |
5 Year Change | 188.80% |
Change since IPO | 754.86% |
Recent News & Updates
Recent updates
Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money
May 23A Look At The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Mar 29What Kind Of Shareholders Hold The Majority In LegoChem Biosciences, Inc.'s (KOSDAQ:141080) Shares?
Jan 28Estimating The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Dec 07Shareholder Returns
A141080 | KR Life Sciences | KR Market | |
---|---|---|---|
7D | 4.0% | -2.5% | 0.2% |
1Y | 107.2% | 0.6% | 7.2% |
Return vs Industry: A141080 exceeded the KR Life Sciences industry which returned 0.6% over the past year.
Return vs Market: A141080 exceeded the KR Market which returned 7.2% over the past year.
Price Volatility
A141080 volatility | |
---|---|
A141080 Average Weekly Movement | 7.7% |
Life Sciences Industry Average Movement | 5.8% |
Market Average Movement | 5.0% |
10% most volatile stocks in KR Market | 11.1% |
10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A141080 has not had significant price volatility in the past 3 months.
Volatility Over Time: A141080's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 135 | Yong Kim | www.legochembio.com |
LigaChem Biosciences Inc. a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, and oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It offers its products in the forms of tablets and capsules.
LigaChem Biosciences Inc. Fundamentals Summary
A141080 fundamental statistics | |
---|---|
Market cap | ₩2.72t |
Earnings (TTM) | -₩46.54b |
Revenue (TTM) | ₩57.54b |
47.4x
P/S Ratio-58.5x
P/E RatioIs A141080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A141080 income statement (TTM) | |
---|---|
Revenue | ₩57.54b |
Cost of Revenue | ₩15.79b |
Gross Profit | ₩41.75b |
Other Expenses | ₩88.30b |
Earnings | -₩46.54b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.28k |
Gross Margin | 72.56% |
Net Profit Margin | -80.88% |
Debt/Equity Ratio | 1.9% |
How did A141080 perform over the long term?
See historical performance and comparison